Absci Corporation reported $1.6M of revenue over the trailing twelve months, −62% on the year before. 9 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $1.6M (to Q2 2026). Net Income: −$121M, trailing twelve months to Q2 2026. Free Cash Flow: −$109M, trailing twelve months to Q2 2026. Op Margin: −9460%, trailing twelve months to Q2 2026.

ABSIAbsci Corporation

HealthcareUSD

$9.22

$2.3052 weeks$10.59

ABSI as reported

Absci Corporation reported $1.6M of revenue over the trailing twelve months, −62% on the year before. 9 reported series are charted on this page, each one as filed.

$1.6M

Revenue, trailing twelve months · to Q2 2026 · −62% against the twelve months before

Net Income: −$121M
Net Income · +6.9% year on year · trailing twelve months to Q2 2026
Free Cash Flow: −$109M
Free Cash Flow · +42% year on year · trailing twelve months to Q2 2026
Op Margin: −9460%
Op Margin · trailing twelve months to Q2 2026

Every series Ryufin has for ABSI, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$1.6M	−62%	Q2 2026
Net Income	−$121M	+6.9%	Q2 2026
EPS	−$0.79	−17%	Q2 2026
Op Margin	−9460%	n/a	Q2 2026
Net Margin	−9088%	n/a	Q2 2026
ROE	−58%	n/a	Q2 2026
ROA	−51%	n/a	Q2 2026
ROIC	−199%	n/a	Q2 2026
Free Cash Flow	−$109M	+42%	Q2 2026